Journal of Shanghai Jiao Tong University (Medical Science) ›› 2022, Vol. 42 ›› Issue (8): 1131-1138.doi: 10.3969/j.issn.1674-8115.2022.08.019

• Review • Previous Articles    

Advances in application of adipose-derived mesenchymal stem cells in autoimmune diseases

LI Yuehua(), LI Qingfeng, XIE Yun()   

  1. Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
  • Received:2022-03-23 Accepted:2022-06-23 Online:2022-08-08 Published:2022-08-08
  • Contact: XIE Yun;
  • Supported by:
    National Natural Science Foundation of China(81701917);Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support(20191916)


The occurrence and development of autoimmune diseases is due to the decrease or even destruction of the patient's autoimmune tolerance, and excessive production of autoantibodies and/or sensitized lymphocytes in the body, resulting in histopathological changes and clinical phenotypes. At present, the main clinical treatment is the drug-based non-specific immunosuppression therapy. Although it can relieve some patients' symptoms, for severe patients, the effect is often not ideal. In recent years, with the in-depth study of mesenchymal stem cells (MSCs), people's understanding of their characteristics has gradually expanded from highly self-renewal and differentiation ability to immunomodulatory function. At the same time, the research direction based on MSCs has gradually shifted from regenerative medicine to the field of autoimmunology. With the development of preclinical and clinical trials, systemic or local application of adipose-derived mesenchymal stem cells (AD-MSCs) has been gradually recognized as one of the effective methods for clinical treatment of autoimmune diseases. In this review, the biological characteristics of AD-MSCs and their application to autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, inflammatory bowel disease, systemic scleroderma, and psoriasis, are highlighted.

Key words: adipose-derived mesenchymal stem cells (AD-MSCs), immune regulation, autoimmune diseases, clinical application

CLC Number: